A subgenomic replicon of hepatitis C virus type 3b and its application
By constructing a puc19 vector containing a specific gene sequence and transfecting Huh7.5.1 cells, the problem of failure to effectively construct the HCV3b subgenomic replicon model in the prior art is solved, and efficient RNA replication and drug sensitivity assessment is achieved, providing important research tools.
Patent Information
- Application Number
- CN202311774353.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-21
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2043-12-21
AI Technical Summary
The existing technology has failed to effectively build a subgenomic replicon model for the type 3b (HCV3b) of Hepatitis C virus in Yunnan, China, making it difficult for patients with HCV3b subtype to cure and insufficient drug development tools.
Huh7.5.1 was transfected with puc19 vectors containing the isoleucine mutation of the NS5A protein, the T7 promoter, the 5'UTR of HCV-3b, the Neo gene, the IRES of EMCV, the non-structural protein region of HCV 3b and the 3'UTR Cells were screened through G418 to obtain a subgenomic replicon model of type 3b hepatitis C virus with efficient RNA replication, and their sensitivity to sofosbuvir drugs was initially evaluated.
The HCV 3b subreplicative subsystem that is efficiently replicated in human liver cancer cell lines has been successfully established, providing an important tool for screening anti-hepatitis C virus drugs and studying drug resistance sites, and improving the research capabilities of HCV3b subreplicative drugs development .
Smart Images

Figure CN117737089B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biomedicine, and in particular to a type 3b hepatitis C virus subgenomic replicon and an application thereof. Background Art
[0002] Hepatitis C virus (HCV) is a highly diverse single-stranded positive-strand RNA virus. Hepatitis C virus infection mainly causes liver damage. HCV infection can cause acute and chronic hepatitis. HCV has developed into a major pathogen that causes chronic hepatitis, cirrhosis, and liver cancer. Many patients die from severe liver-related complications, and it has become a global health problem. According to the World Health Organization (WHO), approximately 2.9 million people died from hepatitis C in 2019, most of whom died from cirrhosis and hepatocellular carcinoma (primary liver cancer). The virus was first identified in 1989 by American scientist Horton and his colleagues as a positive clone from a new RNA virus belonging to the Flaviviridae family from the blood of an infected chimpanzee, which was later named hepatitis C virus. The genome of hepatitis C virus is approximately 9600bp. The HCV RNA genome includes a single open reading frame (ORF), as well as 5'UTR and 3'UTR. Under the mediation of the internal ribosome entry site (IRES), it can translate into a polyprotein precursor. Subsequently, the host and viral proteases cleave the polyprotein precursor to release a variety of functional proteins, including structural proteins: Core protein and E1, E2 glycoproteins, and non-structural proteins: p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B.
[0003] HCV is currently prevalent worldwide, and the prevalence of HCV infection varies greatly between regions and countries. The global prevalence of anti-HCV positivity is approximately 1.6%, and the prevalence of HCV RNA positivity is 1.1%. China is one of the countries with the largest number of HCV patients in the world. More than 14% of HCV infections worldwide come from China, with approximately 200,000 new cases each year. It is estimated that 20% of hepatitis C-related cirrhosis and hepatocellular carcinoma deaths occur in China each year, including approximately 360,000 deaths from liver cancer cells.
[0004] The main transmission modes of HCV are blood transmission, sexual transmission, and mother-to-child transmission. Currently, HCV is divided into 8 genotypes and 95 subtypes. The distribution of HCV genotypes in different provinces of China is different. HCV genotype 3 (GT3), especially HCV3b, is the main genotype of the hepatitis C virus population in Yunnan, and its incidence rate (33.1%; 28.8%-37.6%) is significantly higher than that in other provinces.
[0005] In the era of direct-acting antivirals (DAA), HCV GT3 patients have become the most difficult to treat even with the use of pan-genotypic DAAs. With the recent emergence of pan-genotypic DAAs, HCV sustained virologic response (SVR) rates can reach more than 95% regardless of the presence of cirrhosis or resistance-associated substitutions (RAS). However, compared with other genotypes, GT3 has a lower SVR, and the presence of baseline RAS may affect the response to DAA treatment, especially in patients with cirrhosis. Compared with other genotypes, patients with HCV genotype 3 (GT3) have a significantly higher risk of fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) than patients with other genotypes, especially those with HCV3b subtype, and HCV3b subtype patients remain difficult to cure.
[0006] HCV replicon is a subgenomic RNA molecule that can replicate autonomously in liver cancer cells. The replicon is mainly composed of a segment of HCV non-structural protein NS3-NS5B sequence, the 5′UTR and 3′UTR of the replication key region, a selectable marker gene - usually the neomycin phosphotransferase gene (Neo gene), and a self-replicating bicistronic viral RNA that encodes enzymes required for viral replication. The expression of the first cistron of bicistronic HCV is driven by the IRES of HCV, which usually encodes a reporter gene and a selectable marker gene (Neo gene), and the expression of the second cistron is driven by the IRES of EMCV, which mainly encodes the non-structural protein of HCV. After the replicon clone is transcribed into RNA in vitro, it is transfected into human liver cancer cell lines such as Huh7, and cell clones with high-level replication of HCV RNA can be obtained after G418 resistance screening.
[0007] The HCV subgenomic replicon system can partially simulate the real replication cycle of HCV but does not produce infectious virus particles. The level of HCV replication can be evaluated by measuring the levels of HCV positive and negative strand RNA and non-structural proteins. Since its establishment, the HCV replicon system has played a very important role in the research and development of DAAs. Replicons have become an indispensable tool for functional studies of non-structural proteins, screening of targeted antiviral drugs, DAAs research, antiviral host targets and drug resistance research.
[0008] At present, according to literature reports, success has been achieved in the construction of HCV1a, 1b, 2a, 3a, 4a, 5a and 6a replicons, but there is no replicon model for my country's type 3b HCV strain; however, studies have shown that other genotypes find it difficult to generate effectively replicative RNA, so there is an urgent need to further develop, expand and improve the virological tools used for HCV 3b research and drug development. Summary of the invention
[0009] In view of the shortcomings of the prior art, the present invention provides a type 3b hepatitis C virus subgenomic replicon, whose nucleotide sequence is as shown in SEQ ID NO: 1, which includes a mutation of serine at position 232 on the NS5A protein to isoleucine, the nucleotide sequence at positions 1-23 in the replicon sequence is a T7 promoter sequence, the nucleotide sequence at positions 24-419 is the 5′UTR and part of the Core sequence of HCV-3b, the nucleotide sequence at positions 420-1232 is the Neo gene sequence, the nucleotide sequence at positions 1233-1863 is the IRES sequence of EMCV, the nucleotide sequence at positions 1864-7833 is the non-structural gene (NS3-NS5B) sequence of the virus, the nucleotide sequence at positions 7834-8044 is the 3′UTR sequence of HCV-3b, the nucleotide sequence at positions 8045-8054 is the SPEI restriction site, and the nucleotide sequence at positions 8055-10740 is the backbone plasmid puc19 sequence.
[0010] Another object of the present invention is to apply the hepatitis C virus type 3b subgenomic replicon in screening anti-hepatitis C virus drugs.
[0011] The present invention constructs the Neo gene, IRES of EMCV, 5′UTR of HCV 3b, a partial Core sequence of HCV 3b, NS3-NS5B region of HCV3b, and 3′UTR of HCV 3b together on a puc19 vector, and then transfects the vector into Huh7.5.1 cells. Neo resistance genes are screened by adding G418. Surviving cells carry the Neo gene and related sequences of HCV 3b subreplicons, and HCV RNA can be effectively replicated in stably replicating cultured cells.
[0012] The present invention reports for the first time the establishment of an HCV 3b subreplicon that replicates efficiently in a human hepatoma cell line. The subreplicon system introduces the amino acid substitution S232I of NS5A, and a preliminary evaluation of the EC50 of sofosbuvir is performed on the subreplicon cells stably expressing the mutation.
[0013] The method for constructing the hepatitis C virus type 3b subgenomic replicon of the present invention is as follows:
[0014] (1) Preparation of seamless cloning fragments of HCV 3b;
[0015] (2) The three seamless cloned long fragment gel recovery products were connected using a seamless cloning kit to construct an HCV 3b subreplicon vector carrying puc19;
[0016] (3) After the original plasmid in step (2) is sequenced and verified to be correct, the HCV 3b subreplicon NS5AS232I adaptive point mutation plasmid is modified on this basis to obtain the puc19-HCV-3b-S232I subreplicon plasmid;
[0017] (4) linearizing the puc19-HCV-3b-S232I subreplicon plasmid and then in vitro transcribing it to obtain the corresponding RNA;
[0018] (5) transfecting the RNA obtained by in vitro transcription in step (4) into human liver cancer Huh7.5.1 cells;
[0019] (6) after transfection, use corresponding resistance screening reagents to perform resistance screening;
[0020] (7) The resistance-screened cells were verified by real-time PCR and RT-PCR, i.e., subreplicon cells at the molecular level. The human liver cancer cell line with effective HCV RNA replication was found to contain hepatitis C virus subreplicons.
[0021] The resistance screening gene is the Neo resistance gene, and the resistance screening reagent is G418; during resistance screening, the final concentration of G418 is 1000 μg / mL, and the culture medium containing G418 is replaced every two days, and the screening is continued for 3-4 weeks.
[0022] Advantages and technical effects of the present invention:
[0023] The present invention transforms the viral genome through molecular cloning and seamless cloning technology: the Neo gene, the IRES of EMCV, the 5′UTR of HCV-3b, the partial Core sequence of HCV 3b, the NS3-NS5B region of HCV-3b, and the 3′UTR of HCV-3b are constructed together on the puc19 vector, and after 3-4 weeks of screening by adding G418, a type 3b hepatitis C virus subgenomic replicon model with efficient RNA replication is obtained. The RNA replication of the subgenomic replicon model is very efficient. The present invention also uses the replicon system to detect its sensitivity to the sofosbuvir drug, proving that the replicon can be applied to the screening of hepatitis C virus drugs. The type 3b hepatitis C virus subgenomic replicon of the present invention provides an important research tool for research in the fields of HCV resistance site analysis, adaptive mutation function, HCV pathogenic mechanism and vaccine development. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 This is a schematic diagram of the structure of the hepatitis C virus type 3b subgenomic replicon of the present invention;
[0025] Figure 2 The figure is a graph showing the detection results of three long fragments in Example 1 by agarose gel electrophoresis, wherein lanes 1-4 correspond to three seamless cloned long fragments of DNA Marker, 4-7-wfkl, 8-11-wfkl, and puc19-wfkl, respectively, and lane 5 is a negative control;
[0026] Figure 3 The linearized agarose gel electrophoresis images of the two subreplicon plasmids in Example 2, wherein the left image is puc19-HCV-3b-S232I and the right image is puc19-HCV-3b-S282T;
[0027] Figure 4 The results of real-time fluorescence quantitative PCR detection of HCV RNA load in two subreplicon cells Huh7.5.1-S232I and Huh7.5.1-S282T in Example 3;
[0028] Figure 5 This is an agarose gel electrophoresis diagram of the target fragment amplified by RT-PCR in two subreplicon cells Huh7.5.1-S232I and Huh7.5.1-S282T in Example 4;
[0029] Figure 6 The Sanger sequencing peak diagram of the PCR products of the two subreplicon cells Huh7.5.1-S232I and Huh7.5.1-S282T in Example 4 verifies the mutation site detection results;
[0030] Figure 7This is a graph showing the effects of the two subreplicon cells Huh7.5.1-S232I and Huh7.5.1-S282T in Example 5 on different concentrations of the antiviral drug sofosbuvir. DETAILED DESCRIPTION
[0031] The present invention is further described in detail below by examples and drawings, but the scope of the present invention is not limited to the contents. The methods in the examples are carried out according to conventional operations unless otherwise specified, and the reagents used are conventionally purchased reagents or reagents prepared according to conventional methods unless otherwise specified.
[0032] Example 1: Construction of puc19-HCV-3b subreplicon vector
[0033] 1. Amplification of HCV NS3-NS5B
[0034] The sample came from the HCV 3b subtype numbered QJ013 in our laboratory. Viral RNA was extracted using a viral genomic DNA / RNA extraction kit (Tiangen Biochemical Technology Co., Ltd.). The specific steps are as follows:
[0035] 1) Prepare carrier RNA solution: centrifuge lyophilized powder containing 310 μg carrier RNA to the bottom of the tube, then add 310 μL RNase-Free ddH2O and shake to completely dissolve to obtain a carrier RNA solution with a final concentration of 1 μg / μL, and store at -20°C;
[0036] 2) Preparation of carrier RNA working solution: 0.22 mL of GB solution plus 6.2 μL of 1 μg / μL carrier RNA solution per sample;
[0037] 3) In a clean 1.5 mL centrifuge tube, add 20 μL of Proteinase K solution using a micropipette;
[0038] 4) After the plasma / serum sample is equilibrated to room temperature, take 200 μL and add it to the above centrifuge tube;
[0039] 5) Add 200 μL of Carrier RNA working solution to the upper tube and vortex for 15 seconds to mix thoroughly;
[0040] 6) Incubate at 56°C for 15 min and centrifuge to collect the liquid attached to the tube wall and tube cap;
[0041] 7) Take 250 μL of anhydrous ethanol and add it to the upper tube. Flocculent precipitation may appear at this time. Vortex and shake for 15 seconds to mix thoroughly. Incubate at room temperature for 5 minutes. If the ambient temperature is higher than 25°C, the anhydrous ethanol needs to be pre-cooled.
[0042] 8) Quickly separate to collect the liquid attached to the tube wall and tube cover;
[0043] 9) Transfer all the above liquids to the adsorption column CR2, centrifuge at 8000 rpm for 1 min, discard the waste liquid, and reuse the collection tube;
[0044] 10) Take 500 μL of GD buffer (before use, confirm whether a certain amount of anhydrous ethanol has been added) and add it to the adsorption column. Centrifuge at 8000 rpm for 1 min, discard the waste liquid, and reuse the collection tube;
[0045] 11) Take 600 μL of PW rinse solution (before use, confirm whether a certain amount of anhydrous ethanol has been added) and add it to the adsorption column. Place it at room temperature for 2 minutes, centrifuge it at 8000 rpm for 1 minute, discard the waste liquid, and reuse the collection tube;
[0046] 12) Repeat step 12);
[0047] 13) Take 500 μL of anhydrous ethanol and add it to the adsorption column. Centrifuge at 8000 rpm for 1 min, discard the waste liquid, and reuse the collection tube;
[0048] 14) Centrifuge at 12000 rpm for 3 min to fully dry the adsorption membrane and discard the waste liquid;
[0049] 15) Place a 1.5mL RNase-Free centrifuge tube into the adsorption column, open the cap of the adsorption column, and leave it at room temperature for 3 minutes to allow the adsorption film to completely dry. Add 40μL RNase-Free ddH2O to the middle part of the adsorption film in midair, cover the tube, leave it at room temperature for 5 minutes, and centrifuge at 12000rpm for 1 minute to elute the RNA into a 1.5mL EP tube; divide the RNA according to the experimental needs and freeze it at -80℃ for later use.
[0050] 2. The viral RNA obtained in step 1 was reverse transcribed and used as a template. P510 high-fidelity enzyme was used for PCR amplification. Primers NS_F and 7R, 8F and NS_R were used to amplify two fragments of 2832 bp and 3209 bp, respectively. The reaction system and reaction primers are shown in the following table. PCR reaction conditions: 98°C for 30 s; 98°C for 10 s, 60°C for 5 s, 72°C for 5 s, 35 cycles; 72°C for 1 min;
[0051]
[0052]
[0053] The above two PCR products were detected by agarose gel electrophoresis. Figure 2As shown, after the band size was correct and single, an agarose gel recovery kit (Omega) was used to recover two long fragment gel recovery products, 4-7-wfkl and 8-11-wfkl (i.e., the NS3-NS5B region of HCV), and the gel recovery operation was carried out according to the instructions of the kit;
[0054] 3. Entrust Sino-US Taihe Biotechnology Co., Ltd. to synthesize the puc19 vector plasmid with T7 promoter gene, 5′UTR of HCV 3b, part of the Core region sequence of HCV3b, Neo gene, IRES of EMCV, and 3′UTR of HCV 3b, and use P510 high-fidelity enzyme for PCR amplification. Using the puc19 vector plasmid synthesized by the company as a template, use primers 3′UTR_F and Neo_R to amplify the PCR product of the puc19 vector with the Neo gene. The reaction system and reaction conditions are the same as step 2. The gel recovery is also performed to obtain a total of 1 long fragment gel recovery product of puc19-wfk with the Neo gene. The results are as follows: Figure 2 As shown;
[0055]
[0056]
[0057] 4. Use the seamless cloning kit (NEB) to connect the three long-fragment gel recovery products obtained in the above steps to construct the HCV-3b subreplicon with puc19. The reaction system is shown in the following table. After gentle mixing, centrifuge for 3-5 seconds, and connect at a constant temperature of 50°C in a PCR instrument for 2 hours. After the connection reaction, take 5 μL of the connection product and add it to 100 μL of DH5α Escherichia coli culture medium, ice bath for 30 minutes; heat shock in a 42°C water bath or metal bath for 45 seconds, take it out and put it on ice for 2 minutes; add 895 μL of liquid LB culture medium without ampicillin, place it at 37°C, 200rpm shaker for 90 minutes; centrifuge at 4000rpm for 5 minutes, remove the supernatant, keep 100-200 μL of the culture solution and mix it by blowing, evenly apply it to LB solid culture medium with ampicillin, and incubate it in a constant temperature incubator at 37°C overnight on an inverted plate;
[0058]
[0059] After overnight culture, a few monoclonal colonies grew on the plate. Use a 10 μL pipette tip to gently pick up the monoclonal colonies and place them in 1 mL of liquid LB medium with ampicillin (ampicillin: LB = 1:1000). Pick up 10 to 20 monoclonal colonies and shake them at 37°C and 200 rpm for about 3 hours. Take 1 μL of the bacterial solution for verification of bacterial solution PCR. The primers and system used for bacterial solution PCR reaction are as follows. Reaction conditions: 98°C for 30 s; 98°C for 10 s, 60°C for 5 s, 72°C for 5 s, 35 cycles; 72°C for 1 min;
[0060]
[0061]
[0062] For the bacterial solution with positive PCR verification results, expand the culture and extract the plasmid. The detailed steps of plasmid extraction are as follows:
[0063] 1) The bacterial solution with positive verification results was centrifuged at 4000 rpm for 15 min, the supernatant was discarded, and 4 mL of bacterial solution was pipetted and mixed evenly, and then added evenly into the sterilized EP tube;
[0064] 2) Centrifuge at 12000 rpm for 1 min and discard the supernatant as much as possible;
[0065] 3) Add 250 μL of P1 solution (check to ensure RNase A has been added before use) to the EP tube containing bacterial pellets, and vortex until the bacterial solution is completely suspended;
[0066] 4) Add 250 μL of P2 solution to the EP tube and gently turn it upside down 6-8 times to fully lyse the bacteria;
[0067] 5) Add 350 μL of P3 solution to the EP tube, and immediately gently turn it upside down 7 times to mix thoroughly. A white flocculent precipitate will appear, and centrifuge at 12,000 rpm for 10 min.
[0068] 6) Column equilibration: Add 500 μL BL equilibration solution to the adsorption column CP3, centrifuge at 12000 rpm for 1 min, discard the waste liquid, and reuse the collection tube;
[0069] 7) After centrifugation in step 5), collect the supernatant, try not to suck up the precipitate, add it to the adsorption column CP3 in step 6), centrifuge at 12000 rpm for 1 min, discard the waste liquid, and reuse the collection tube;
[0070] 8) Add 500 μL of PD deproteinized solution to the adsorption column CP3, centrifuge at 12000 rpm for 1 min, discard the waste liquid, and reuse the collection tube;
[0071] 9) Add 600 μL of PW rinse solution to the adsorption column CP3, centrifuge at 12000 rpm for 1 min, discard the waste liquid, and reuse the collection tube;
[0072] 10) Repeat step 9;
[0073] 11) Centrifuge at 12000 rpm for 2 min to remove the residual liquid in the adsorption column CP3. After centrifugation, open the lid and place it in a vent to allow the residual liquid in the adsorption membrane to fully dry;
[0074] 12) Place the adsorption column CP3 in a clean EP tube, drip 50-100 μL of 56°C preheated sterile water into the middle of the adsorption column, let stand at room temperature for 2 minutes, and centrifuge at 12000 rpm for 2 minutes to collect the plasmid solution in the EP tube.
[0075] 5. After the plasmid extracted in step 4 was sequenced and verified to be correct, the HCV 3b subreplicon NS5A S232I adaptive point mutation plasmid was modified. The plasmid extracted in step 4 was used as a template to design S232I point mutation primers. The primer sequences are shown below, and PCR amplification was performed according to the reaction system shown in the following table. The reaction conditions were: 98°C for 30s; 98°C for 10s, 60°C for 5s, 72°C for 5s, 35 cycles; 72°C for 1min; after the amplification, agarose gel electrophoresis was performed to detect the target band, and after confirming the target band, DpnI was used for digestion to remove the methylated template plasmid. The reaction system was as follows. After gently blowing and mixing, the plasmid was placed in a 37°C constant temperature incubator for reaction for 1h. After the digestion, the gel was recovered to purify the target amplification product, thereby obtaining the puc19-HCV-3b-S232I subreplicon plasmid ( Figure 1 );
[0076]
[0077] The S232I subreplicon plasmid amplification reaction system is as follows
[0078]
[0079] The DpnI digestion reaction system is as follows
[0080]
[0081] 6. At the same time, prepare puc19-HCV-3b-S282T subreplicon plasmid as a control. Using the puc19-HCV-3b-S232I subreplicon plasmid obtained in step 5 as a template, design S282T point mutation primers. The specific primer sequences are shown below. Perform PCR amplification according to the reaction system and conditions of step 5. After amplification, perform agarose gel electrophoresis to detect. After confirming the target band, use DpnI to digest to remove the methylated template plasmid. The reaction system is the same as step 5. After gently blowing and mixing, place in a 37°C constant temperature incubator for reaction for 1 to 2 hours. After digestion, perform gel recovery to purify the target amplification product to obtain the puc19-HCV-3b-S282T subreplicon plasmid.
[0082]
[0083] Example 2: Construction of stably transfected cells carrying subgenomic replicons of hepatitis C virus type 3b
[0084] 1. In vitro transcription: After the subreplicon plasmid in Example 1 was sequenced and verified to be correct, the subreplicon plasmid was linearized using SpeⅠ restriction enzyme, and the linearized product was detected by electrophoresis. The result was as follows: Figure 3 As shown, it indicates that the linearized plasmid is successful. Take 1 μg of the linearized enzyme digestion product and use the T7 in vitro transcription kit to react in a PCR instrument at 37°C for 4 hours to synthesize the RNA chain;
[0085] 2. After in vitro transcription, RNA purification is performed;
[0086] 3. Transfection: Take 4 μL DMRIE-C and add it to 500 μL Opti-MEM serum-free medium. Vortex gently and spin it off. Add 3 μg of in vitro transcribed RNA purified in step 2 to Opti-MEM. Then, immediately drip the Opti-MEM solution slowly into the well plate. After 5 hours, change the cells to DMEM medium without double antibody and containing 10% FBS.
[0087] 4. Screening of cells with Neo resistance: Add resistance screening agent G418 to DMEM medium containing 1% double antibody and 10% FBS, the final concentration of G418 is 1000 μg / mL, replace the medium containing G418 every two days, after 4 weeks of continuous screening, no dead cells will appear in the cell culture process, at this time there will be sporadic cell colonies in the well plate, and the cell colonies will be expanded and cultured, and the G418 maintenance concentration of the expanded culture is 1 / 2 of the screening concentration, i.e. 500 μg / mL; obtain two stable cells of 3b hepatitis C virus subgenomic replicons, namely Huh7.5.1-S232I and Huh7.5.1-S282T.
[0088] Example 3: Real-time fluorescence quantitative PCR detection
[0089] Total RNA from Huh7.5.1 cells, Huh7.5.1-S232I cells, and Huh7.5.1-S282T cells was extracted by hand extraction RNAiso Plus (Takara), and then the RNA loading of all transfected subreplicon cells was detected by probe-based absolute quantitative PCR. The quantitative primers, probes, and reaction system were as follows: 45°C for 5 min; 95°C for 10 s; 95°C for 5 s, 58°C for 45 s, and 40 cycles. The results are shown in the figure. Figure 4 As shown, the loads of Huh7.5.1-S232I cells and Huh7.5.1-S282T cells were significantly higher than those of Huh7.5.1 cells. The results of Huh7.5.1 cells may be caused by system errors, indicating that the two constructed HCV3b subreplicons were successfully transfected in the cells;
[0090]
[0091]
[0092] Example 4: RT-PCR detection of mutation sites
[0093] 1. Total RNA of Huh7.5.1-S232I cells and Huh7.5.1-S282T cells was extracted by hand extraction RNAiso Plus (Takara), and RNA was used as a template for one-step RT-PCR amplification. The reverse transcription primers (3b10F01 and 3b10R01) and reaction system used were as follows: 50°C 30min; 94°C 3min; 94°C 30s, 50°C 30s, 72°C 2min, 40 cycles; 72°C 7min; the kit used was PrimeScript TM One Step RT-PCR Kit (RR055A), product length 1181 bp;
[0094]
[0095]
[0096] 2. Use the PCR product obtained in step 1 as the peripheral template to amplify the inner PCR. The primers (3b10F02 and 3b10R02) and reaction system used are as follows: 94°C for 5 min; 94°C for 30 s, 50°C for 30 s, 72°C for 1 min 30 s, 40 cycles; 72°C for 7 min; the DNA enzyme used is Vazyme's Green Taq Mix enzyme, and the product length is 932 bp.
[0097]
[0098]
[0099] The point mutation sites of the two transfected replicon cells were verified by RT-PCR, and the fragment sizes were consistent with the target fragment size. The results are as follows Figure 5 As shown, the PCR product of the target band was subjected to Sanger sequencing, and the sequencing result peak was single and complete, as shown in Figure 6 As shown, it was shown that the two constructed HCV3b original and point mutation replicons were successfully transfected into cells and retained the previously modified point mutation sites.
[0100] Example 5: Detection of sensitivity of subreplicon stably transfected cells Huh7.5.1-S232I and Huh7.5.1-S282T to sofosbuvir
[0101] In a 12-well plate, 1.5-2×10 5 The stably transfected Huh7.5.1-S232I and Huh7.5.1-S282T cells were inoculated with 100 μg / mL of RNAiso Plus (Takara) and cultured in a CO2 constant temperature incubator (Thermo, USA) at 37°C and 5% CO2 for 24 h. After the cells adhered to the wall and the cell quantity and state were good, they were treated with different concentrations of sofosbuvir as shown in the following table. After 72 h of drug treatment, 500 μL of cells were collected per well using RNAiso Plus (Takara), and the nucleic acids of cells with different drug concentrations were extracted by hand-lifting. The nucleic acid concentration was determined using Tiangen UV spectrophotometer, and the loading amount was calculated (i.e., the purpose of ensuring a uniform loading amount is to ensure absolute quantification). The loading amount used in this example is 1500 ng, and the kit used is One Step PrimeScript TM RT-PCR Kit (RR064A) was used to detect the HCV viral load in the collected cells after the above drugs were applied by real-time fluorescence quantitative method. The quantitative results were processed by Excel software, and then the graphs were drawn and EC50 (half-maximal effect concentration, i.e., the drug concentration that inhibits 50% of the viral load) was calculated using Graphpad Prism 5 software. The results are shown in Figure 7As shown, the EC50 (uM) values of sofosbuvir for Huh7.5.1-S232I and Huh7.5.1-S282T cells were approximately 103.5 and 566.3, respectively. The results showed that Huh7.5.1-S232I cells showed higher sensitivity to the anti-HCV drug sofosbuvir. Therefore, the subreplicon cells can be used as a favorable tool for subsequent screening of other anti-HCV drugs and discovery of new drug-resistant mutation sites.
[0102]
Claims
1. A hepatitis C virus type 3b subgenomic replicon, characterized in that: The replicon nucleotide sequence is as shown in SEQ ID NO:
1.
2. Use of the hepatitis C virus type 3b subgenomic replicon according to claim 1 in screening anti-hepatitis C virus drugs.
Citation Information
Patent Citations
Novel recombinant human hepatitis C virus-like particle and method for producing the same
AU2006295716A1
Mutant replicon derived from genome of hepatitis c virus j6cf strain
CN103703133A
Nucleic acid construct including nucleic acid derived from genotype 3[alpha] HCV genome
CN104126008A
Type 3a hepatitis C virus subgenome replicon and application
CN113862231A
6a type hepatitis C virus subgenome replicon and application thereof
CN113881643A
